244 related articles for article (PubMed ID: 24327541)
21. Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy.
Atwal M; Lishman EL; Austin CA; Cowell IG
Mol Pharmacol; 2017 Jan; 91(1):49-57. PubMed ID: 27974636
[TBL] [Abstract][Full Text] [Related]
22. Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints.
Lovett BD; Strumberg D; Blair IA; Pang S; Burden DA; Megonigal MD; Rappaport EF; Rebbeck TR; Osheroff N; Pommier YG; Felix CA
Biochemistry; 2001 Feb; 40(5):1159-70. PubMed ID: 11170441
[TBL] [Abstract][Full Text] [Related]
23. A novel four-way t(6;16;21;8)(p21.3;p11.2;q22;q22) in acute myeloid leukemia with RUNX1/RUNX1T1 rearrangement.
Park KJ; Park HD; Kim HJ; Yoo KH; Koo HH; Kim SH
Cancer Genet Cytogenet; 2009 Jul; 192(2):90-2. PubMed ID: 19596262
[No Abstract] [Full Text] [Related]
24. Inhibition of DNA topoisomerase II with etoposide induces association of DNA topoisomerase II alpha, DNA topoisomerase II beta, and nucleolin with BCR 2 of the ETO gene.
Rubtsov MA; Razin SV; Iarovaia OV
Dokl Biochem Biophys; 2008; 423():334-6. PubMed ID: 19230382
[No Abstract] [Full Text] [Related]
25. Rearrangement of VPS13B, a causative gene of Cohen syndrome, in a case of RUNX1-RUNX1T1 leukemia with t(8;12;21).
Abe A; Yamamoto Y; Katsumi A; Okamoto A; Tokuda M; Inaguma Y; Yamamoto K; Yanada M; Kanie T; Tomita A; Akatsuka Y; Okamoto M; Kameyama T; Mayeda A; Emi N
Int J Hematol; 2018 Aug; 108(2):208-212. PubMed ID: 29264741
[TBL] [Abstract][Full Text] [Related]
26. Clinical Relevance of RUNX1 and CBFB Alterations in Acute Myeloid Leukemia and Other Hematological Disorders.
Metzeler KH; Bloomfield CD
Adv Exp Med Biol; 2017; 962():175-199. PubMed ID: 28299658
[TBL] [Abstract][Full Text] [Related]
27. RUNX1-Evi-1 fusion gene inhibited differentiation and apoptosis in myelopoiesis: an in vivo study.
Shen L; Zhu J; Chen F; Lin W; Cai J; Zhong J; Zhong H
BMC Cancer; 2015 Dec; 15():970. PubMed ID: 26674644
[TBL] [Abstract][Full Text] [Related]
28. Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML.
Lei YC; Chen XJ; Dai YT; Dai B; Wang JY; Li MH; Liu P; Liu H; Wang KK; Jiang L; Chen B
Acta Pharmacol Sin; 2024 Mar; 45(3):633-645. PubMed ID: 38017299
[TBL] [Abstract][Full Text] [Related]
29. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
Senyuk V; Sinha KK; Li D; Rinaldi CR; Yanamandra S; Nucifora G
Cancer Res; 2007 Jun; 67(12):5658-66. PubMed ID: 17575132
[TBL] [Abstract][Full Text] [Related]
30. t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy.
Yin CC; Cortes J; Barkoh B; Hayes K; Kantarjian H; Jones D
Cancer; 2006 Apr; 106(8):1730-8. PubMed ID: 16532439
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous occurrence of BCR/ABL1 and RUNX1/RUNX1T1 in a case of therapy-related acute myeloid leukemia.
Ammatuna E; Divona M; Curzi P; Panetta P; Zaza S; Postorino M; Cantonetti M; Amadori S; Lo Coco F
Cancer Genet Cytogenet; 2009 Dec; 195(2):189-91. PubMed ID: 19963124
[No Abstract] [Full Text] [Related]
32. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
33. [Near-tetraploidy acute myeloid leukemia with RUNX1-RUNX1T1 rearrangement due to cryptic t(8;21)].
Im M; Lee JK; Lee DY; Hong YJ; Hong SI; Kang HJ; Chang YH
Korean J Lab Med; 2009 Dec; 29(6):510-4. PubMed ID: 20046081
[TBL] [Abstract][Full Text] [Related]
34. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
35. Role of the RUNX1-EVI1 fusion gene in leukemogenesis.
Maki K; Yamagata T; Mitani K
Cancer Sci; 2008 Oct; 99(10):1878-83. PubMed ID: 19016745
[TBL] [Abstract][Full Text] [Related]
36. AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia.
Meyers S; Lenny N; Sun W; Hiebert SW
Oncogene; 1996 Jul; 13(2):303-12. PubMed ID: 8710369
[TBL] [Abstract][Full Text] [Related]
37. Altered chromatin modifications in AML1/RUNX1 breakpoint regions involved in (8;21) translocation.
Stuardo M; Martinez M; Hidalgo K; Montecino M; Javed A; Lian JB; Stein GS; Stein JL; Gutiérrez SE
J Cell Physiol; 2009 Feb; 218(2):343-9. PubMed ID: 18853425
[TBL] [Abstract][Full Text] [Related]
38. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia.
Liu S; Shen T; Huynh L; Klisovic MI; Rush LJ; Ford JL; Yu J; Becknell B; Li Y; Liu C; Vukosavljevic T; Whitman SP; Chang KS; Byrd JC; Perrotti D; Plass C; Marcucci G
Cancer Res; 2005 Feb; 65(4):1277-84. PubMed ID: 15735013
[TBL] [Abstract][Full Text] [Related]
39. Submicroscopic deletion of RUNX1T1 gene confirmed by high-resolution microarray in acute myeloid leukemia with RUNX1/RUNX1T1 rearrangement.
Yang JJ; Oh SH; Cho SY; Suh JT; Lee HJ; Lee WI; Lee J; Baek SK; Yoon HJ; Cho EH; Park TS
Acta Haematol; 2012; 127(1):43-6. PubMed ID: 22025082
[No Abstract] [Full Text] [Related]
40. ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation.
Hartmann L; Dutta S; Opatz S; Vosberg S; Reiter K; Leubolt G; Metzeler KH; Herold T; Bamopoulos SA; Bräundl K; Zellmeier E; Ksienzyk B; Konstandin NP; Schneider S; Hopfner KP; Graf A; Krebs S; Blum H; Middeke JM; Stölzel F; Thiede C; Wolf S; Bohlander SK; Preiss C; Chen-Wichmann L; Wichmann C; Sauerland MC; Büchner T; Berdel WE; Wörmann BJ; Braess J; Hiddemann W; Spiekermann K; Greif PA
Nat Commun; 2016 Jun; 7():11733. PubMed ID: 27252013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
